Treatment of Acid-related Diseases Using Potassium-competitive Acid Blockers

Treatment of Acid-related Diseases Using Potassium-competitive Acid Blockers

Blog Article

Proton pump inhibitors (PPIs) have several limitations to bolia outlet gent their efficacy including insufficient acid suppression, slow onset of action, and variable efficacy among patients due to CYP2C19 metabolism.Potassium-competitive acid blockers inhibit H+-K+-ATPase in a reversible and K+-competitive manner, are novel acid suppressive drugs with rapid onset of action, meal independence, and prolonged control fleshlight automatique of intragastric acidity compared to PPIs.Potassium-competitive acid blockers exhibited non-inferior therapeutic efficacies on reflux esophagitis, gastric ulcers, and Helicobacter pylori eradication.The review is focused on the unmet needs across the acid-related diseases and recent updates on clinical studies using vonoprazan and tegoprazan.